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Available online 22 November 2015We sought to determine if a selective HDAC6 inhibitor (ACY-738) decreases disease in NZB/Wmice. From 22 to
38 weeks-of-age, mice were injected intraperitoneally with 5 or 20 mg/kg of ACY-738, or vehicle control. Body
weight and proteinuria were measured every 2 weeks, while sera anti-dsDNA, Ig isotypes, and cytokine levels
weremeasured every 4weeks. Kidney diseasewas determined by evaluation of sera, urine, immune complex de-
position, and renal pathology. Flow cytometric analysis assessed thymic, splenic, bone marrow, and peripheral
lymphocyte differentiation patterns. Our results showed HDAC6 inhibition decreased SLE disease by inhibiting
immune complex-mediated glomerulonephritis, sera anti-dsDNA levels, and inﬂammatory cytokine production
and increasing splenic Treg cells. Inhibition of HDAC6 increased the percentage of cells in the early-stage develop-
mental fractions of both pro- and pre-B cells. These results suggest that speciﬁc HDAC6 inhibitionmay be able to
decrease SLE disease by altering aberrant T and B cell differentiation.
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T cells1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that
can affect nearly every organ in the body [1]. A pathognomonic feature
of lupus nephritis is B cell dysregulation leading to autoantibody pro-
duction and immune-complexmediated glomerulonephritis [2]. Hyper-
active B cells contribute to SLE pathogenesis by inducing CD4+ T helper
cells, inhibiting regulatory T (Treg) cells, secreting proinﬂammatory cy-
tokines, and producing autoantibodies [3]. Reduced Treg cell numbers
and function have been reported during active SLE in both mice and
humans, which contributes to immune dysregulation and a lack of
self-tolerance [4]. Furthermore, TH17/Treg imbalance has been associat-
ed with the development of inﬂammatory disorders and renal dysfunc-
tion [5,6,7]. Female New Zealand Black/White (NZB/W) mice mimic
human disease in several ways and therefore serve as an acceptable
model of SLE. NZB/W mice are generated from the cross of New
Zealand Black/BinJ (NZB) and New Zealand White/LacJ (NZW) mice
and develop a spontaneous lupus-like disease [8]. Both NZB/W mice
and humans with active SLE produce autoantibodies against double-College of VeterinaryMedicine,
s.
. This is an open access article understranded DNA (dsDNA) and histones and develop immune complex-
mediated glomerulonephritis [9].
B cells originate from pluripotent hematopoietic stem cells in the
BM. Once the B cell pathway has been selected, B cell development
and differentiation occurs in a series of stages, progressing from pro-
to pre-, to immature B cells [10]. Pro-B cells (B220+CD43+) pass
through 4 developmental phases: A (CD24−BP1−), B (CD24+BP1−), C
(CD24loBP1+), and C′ (CD24hiBP1+), while undergoing heavy chain
D–J and V(D)J rearrangement [11,12]. Following successful IgG heavy
chain rearrangement, CD43 expression is downregulated and cells prog-
ress into the pre-B cell (B220+CD43−) phase. Pre-B cells pass through 3
fractions: D (IgM− IgD−), E (IgM+IgD−), and F (IgM+IgD+) [11].
Fraction D cells rearrange Ig light chains, begin to express IgM and differ-
entiate into fraction E or immature B cells [13]. Fraction E cells exit the
BM and continue to mature in the spleen. As IgM+ immature B cells
begin to express IgD, they progress into fraction F, or mature B cells [11].
Hyperactive B and/or T cells contribute to SLE, however, the underly-
ing mechanism remains unclear [2,14,15]. A number of possible causes
havebeen identiﬁed including intrinsic hyper-reactivity resulting in poly-
clonal B cell activation, defective negative selection, decreased immuno-
regulatory functions, and altered cytokine production inﬂuencing B cell
activity [16,17]. Research in both patients with SLE and murine models
has shown abnormalities in B cell development and differentiation [2,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment in the BM, spleen, and periphery [18,19]. Due to the ability of B cells
to act as antigen-presenting cells (APCS), differentiate into antibody-
secreting plasma cells, and secrete immunoregulatory cytokines, agents
that modulate B cells may be of potential therapeutic value [20]. Further-
more, a number of B cell depletion therapies have been investigated for
their effectiveness in treating SLE [21,22,23,24].
Numerous studies have shown that the ability of an organism to
respond to its environment is dependent upon its capacity to modulate
gene expression through chromatin remodeling [25,26]. Cellular function
can be altered by DNA methylation, histone modiﬁcation, and microRNA
signaling [27]. Epigenetic alterations have been noted in the pathogenicity
of various autoimmune diseases [28,29,30,31]. Histone deacetylases
(HDACs) catalyze the removal of acetyl groups from histones restricting
chromatin availability for transcription factor binding. Furthermore,
HDACshavebeen implicated in immune cell regulation andmay therefore
be efﬁcacious as diagnostic or prognostic biomarkers or as targets for the
treatment of autoimmune diseases including SLE [32,33,34,35]. Tradition-
ally, HDACswere thought to function solely through epigenetic regulation
of histone proteins [36]. However, it is now known that HDACs can also
regulate acetylation of over 50 nonhistone proteins, including transcrip-
tion factors, signalingmolecules, DNA repair enzymes, and structural pro-
teins [36,37]. Due to the large number of HDACs that are targeted,
pan-HDAC inhibitors have been associated with many deleterious side
effects during clinical trials including fatigue, nausea, and electrocardio-
graph abnormalities [38,39]. For this reason, selective HDAC inhibitors
are being pursued as more suitable treatments for autoimmune disease.
Multiple class I and II HDACs have been implicated in the regulation of
Foxp3 expression, including HDAC6, HDAC7 and HDAC9 [40,41,42].
HDAC6 is a class IIb HDAC that is located primarily in the cytoplasm
and has been demonstrated to regulate the acetylation of α-tubulin and
HSP90 [43,44]. Treatment with class I and IIb pan-HDAC inhibitors has
been shown to increase Treg populations [5,45,46], however treatment
with selective class I HDAC inhibitors has been shown to have minimal
effect on Treg function or numbers [47]. Therefore, it can be reasoned
that speciﬁc class IIb HDAC inhibition is responsible for Treg function.
The current studies were designed to investigate whether treatment
with a selective HDAC6i would decrease disease in lupus-prone mice
through the regulation of B and/or T cell differentiation. Inhibition of
HDAC6 was chosen due to research in HDAC6 deﬁcient mice showing an
increase in expression of Foxp3 and Treg cells compared to wild type
(WT) mice [39,48]. Furthermore, HDAC6 is known to be expressed at
higher levels in Treg cells, which are downregulated during SLE, than in
conventional T cells [43]. HDAC6 inhibition has also been associated with
increased DNA-damage leading to a greater apoptotic rate and index
[48]. HDAC6may be able to regulate B cell differentiation through regula-
tion of apoptosis. For this study we used the selective HDAC6i, ACY-738
(N-hydroxy-2-(1-phenylcycloproylamino) pyrimidine-5-carboxamide).
2. Materials and methods
2.1. ACY-738 bioavailability
Male C57BL/6 mice were injected intraperitoneally (i.p.) with ACY-
738(5mg/kg) in 10% DMAC/10% HS15/80% saline. Plasmawas obtained
from blood collected at various time points. The concentration of ACY-
738 in the plasma was determined by mass spectrometric detection
(LC/MS/MS) and calculated using a standard curve. The pharmacokinet-
ic (PK) parameters were calculated using WinNonlin software.
2.2. Mice
Female NZB/W F1 mice were purchased from Jackson Laboratories
(Bar Harbor, ME, USA). All mice were used in accordancewith the Insti-
tutional Animal Care and Use Committee of Virginia Polytechnic Insti-
tute and State University and housed in the animal facility at theVirginia-Maryland Regional College of Veterinary Medicine (VMRCVM,
Blacksburg, VA, USA).
2.3. In vivo treatment
Mice were injected i.p. 5 days/week with the vehicle control
(DMSO), ACY-738 treatment at 5 mg/kg (low-dose), or ACY-738 treat-
ment at 20 mg/kg (high-dose) beginning at 22-weeks-of-age until eu-
thanasia at 38 weeks-of-age. The total volume injected was 80 μL.
ACY-738 was received as a generous donation from Acetylon Pharma-
ceuticals for use in all studies. Proteinuria and weight were measured
every 2 weeks and blood was collected every four weeks for sera analy-
sis. Proteinuria was measured by a standard semi-quantitative test
using Siemens Uristix dipsticks (Siemens Healthcare, Deerﬁeld, IL,
USA). Results were quantiﬁed according to the manufacturer's instruc-
tions and scored as follows: dipstick reading of 0 mg/dL = 0, trace =
1, 30–100 mg/dL = 2, 100–300 mg/dL = 3, 300–2000 mg/dL = 4, and
2000+mg/dL = 5.
2.4. Measurement of autoantibodies
Sera were collected prior to initiation of treatment at 22 weeks-of-
age and every 4 weeks until euthanasia. The mice were anesthetized
using isoﬂurane (Piramal Healthcare, Mumbai, Maharashtra, India)
and bled from the retro-orbital sinus. Blood was allowed to clot for 2 h
and then centrifuged for 15min at 10,000 ×g. The levels of sera antibod-
ies to dsDNA were measured by ELISA. Sera samples were added to the
plate at a 1:100 dilution, followed by a two-fold serial dilution. The plate
was read at 380 nmon a Spectramax 340PCmicroplate spectrophotom-
eter (Molecular Devices, Sunnyvale, CA, USA). A ﬁnal dilution of 1:800
was reported.
2.5. Isolation of B cells from the BM
BM cells were ﬂushed in PBSwith 1% BSA from the femurs of NZB/W
mice following euthanasia. Red blood cells (RBCs) were lysed using am-
monium chloride potassium (ACK) lysing solution. Single-cell suspen-
sions were then washed and stained with Allo-Phycocyanin (APC)-
conjugated anti-mouse B220 and Fluorescein Isothiocyanate (FITC)-
conjugated anti-mouse CD43 mAbs to identify pro-B cell
(B220+CD43+) and pre-B cell (B220+CD43−) populations. Pro-B cell
populations were further stained with Phycoerythrin (PE)-conjugated
anti-mouse BP1 and PECy5 or Peridinin-chlorophyll proteins (PerCP)-
conjugated anti-mouse CD24 mAbs to identify fractions A (B220+-
CD43+CD24−BP1−), B (B220+CD43+CD24+BP1−), C (B220+CD43+-
CD24loBP1+), and C′ (B220+CD43+CD24hiBP1+). Pre-B cells fractions
were further stained with PE-conjugated anti-mouse IgD and PECy5-
conjugated anti-mouse IgM mAbs to identify fractions D (B220+-
CD43− IgM−IgD−), E (B220+CD43− IgM+IgD−) and F (B220+CD43−-
IgM+IgD+). Fractions were measured by ﬂow cytometric analysis. All
antibodies were purchased from eBioscience (San Diego, CA, USA).
Flow cytometry was performed at the College of Veterinary Medicine
Flow Cytometry Core Facility using a FACScan ﬂow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). Flow cytometry data was analyzed
using FlowJo Software (Tree Star, Ashland, OR, USA).
2.6. Isolation of splenic B cells
Following euthanasia, spleenswere removed and single-cell suspen-
sions of splenocytes were incubated with PerCP710 conjugated IgM,
FITC conjugated AA4.1, PE conjugated CD23, and APC conjugated CD21
anti-mouse mAbs (eBioscience, San Diego, CA, USA). IgM+ cells were
analyzed for the expression of AA4.1, CD23 and CD21 and divided into
the following developmental stages using ﬂow cytometry: T1 (IgM+-
CD23−AA4.1+CD21−), T2 (IgMhiCD23+AA4.1+CD21+), T3 (IgM-
loCD23+AA4.1+CD21+), F0 (IgM+CD23+AA4.1−CD21−), MZ
Fig. 1. Evaluation of pro- and pre-B cells inNZB/Wmice. BM cellswere harvested from pre-diseased and diseasedNZB/Wmice and labeledwith ﬂuorescently tagged antibodies speciﬁc for
pro- and pre-B cells. (A) Representative images of B cells labeled with CD43 and B220. (B) There were no signiﬁcant differences in the percentage of B cells in the pro- or pre-B subsets
between pre-diseased and diseased NZB/W mice. (C) The pro-B cell subset was further divided into fractions A (CD24−BP1−), B (CD24+BP1−), C (CD24loBP1+) and C′ (CD24hiBP1+).
Representative ﬂow cytometry image of pro-B cell fractions A, B, C, and C′ from pre-diseased and diseased NZB/Wmice. (D) Therewere signiﬁcantly fewer pro-B cells in the C and C′ frac-
tions in diseased NZB/Wmice. (E) The pre-B cell subset was further divided into fractions D (IgM−IgD−), E (IgM+IgD−), and F (IgM+IgD+). Representative images of pre-B cell subsets
fromNZB/Wmice. (F) Diseased NZB/Wmice had signiﬁcantly decreased numbers of cells in fraction D and E, yet signiﬁcantly increased percentages of cells in fraction F (n=3; *p b 0.05,
**p b 0.005, ***p b 0.0005).
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Fig. 1 (continued).
61N.L. Regna et al. / Clinical Immunology 162 (2016) 58–73(IgM+CD23−AA4.1−CD21+) or B1 (IgM+CD23−AA4.1−CD21−). Flow
cytometry data was analyzed using FlowJo.
2.7. Isolation of peripheral B cells
Blood was collected prior to euthanasia using retro-orbital bleeding.
RBCs from the peripheral blood were lysed and single cell suspensions
were labeled using FITC-conjugated B220 and PerCep710 conjugated
IgM anti-mouse mAbs (eBioscience, San Diego, CA, USA). Mature B
cells were identiﬁed as IgM+B220+ cells. Flow cytometry data was an-
alyzed using FlowJo.
2.8. Pathology
At the time of euthanasia, the kidneys were removed and cut in half.
One half of the kidney from each mouse was ﬁxed in formalin, embed-
ded in parafﬁn, sectioned, and stained with Periodic acid-Schiff (PAS).Fig. 2. ACY-738 PK parameters. PK data following i.p. injection of 5 mg/kg ACY-738. ACY-738 reKidney sections were scored (0–4) for glomerular proliferation, inﬂam-
mation, crescent formation, necrosis, and by a pathologist, in a blinded
manner.
2.9. Immunoﬂuorescence staining
One half of each kidney was placed in OCTmedia and snap-frozen in
a slurry containing dry ice and 2-methylbutane (Fisher Scientiﬁc,
Hampton, NH, USA). Frozen kidney sectionswere cut into 3 μMsections
and stained with goat anti-mouse IgG conjugated to FITC (Pierce) di-
luted 1:100 or goat anti-mouse C3-FITC (Pierce, Thermo Fisher
Scientiﬁc, Waltham, Massachusetts, USA) diluted 1:100. Kidney sec-
tions were examined by ﬂuorescent microscopy. Sections were
scored (0–4) for immune complex deposition by a pathologist in a
blinded manner.
2.10. Isolation of T cells
A single-cell suspension was obtained from the thymuses and
spleens of treated NZB/Wmice at 38 weeks-of-age. Brieﬂy, the thymus
was removed from each NZB/W mouse and dissociated across a sterile
wiremesh in a petri dish containing ice-cold RPMI 1640medium (Ther-
mo Scientiﬁc). RBCs were lysed using RBC lysis buffer and cells were
pelleted and washed with PBS. Splenocytes were stained with APC-
conjugated anti-mouse CD3 (APC-CD3), FITC-conjugated anti-mouse
CD4 (FITC-CD4), eFluor450 (eF450)-conjugated anti-mouse CD8a,
PerCP-CY5.5-conjugated anti-mouse CD25, and PE-conjugated anti-
mouse Foxp3. Cells were ﬁxed and permeabilized prior to staining
with Foxp3. Thymocytes were stained with APC-CD3, FITC-CD4, and
PE-conjugated anti-mouse CD8 mAbs (eBioscience, San Diego, CA,
USA). Fluorescence was measured using a FACScan ﬂow cytometer
and data was analyzed by FlowJo software.
2.11. Glomerular isolation
The cortical tissue was isolated from one kidney of each mouse and
pooled by treatment group. Brieﬂy, cortical tissue was pressed through
grading sieves and resuspended in 750 U/mLWorthington type I colla-
genase at 37 °C for 20min. Glomerular cells were pelleted, resuspended
in RNAlater (QIAGEN, Valencia, CA, USA), and stored at −20 °C until
RNA isolation.
2.12. Isolation of RNA
RNA was isolated using the mirVana miRNA isolation kit according
to the manufacturer's protocol (Applied Biosystems, Carlsbad, CA,
USA). The eluates were quantiﬁed on a spectrophotometer (Nanodrop,
Thermo Scientiﬁc, Waltham, MA, USA). An aliquot was taken andached a maximum plasma concentration of 1310 ng/mL at 0.0830 h following treatment.
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Fig. 3. HDAC6 inhibition altered pro- and pre-B cell populations in the BM. Harvested BM cells were stained with B220 and CD43. (A) Representative ﬂow cytometry image of pro-B cell
(B220+CD43+) and pre-B cell (B220+CD43−) populations. (B) Therewere no signiﬁcant differences in the percentages of pro-B cells amongst treatment groups. (C) Representative ﬂow
diagram of pro-B cell fractions: A, B, C, and C′. (D) Treatment with ACY-738 signiﬁcantly increased the percentage of pro-B cells in fractions A and C. (E) The percentage of pre-B cells was
signiﬁcantly decreased in a dose-dependent manner following HDAC6i treatment. (F) Representative ﬂow cytometry image of pre-B cell fractions D, E, and F. (G) At 38weeks-of-age, the
percentage of pre-B cells in fractions D and E was signiﬁcantly increased, while the percentage of cells in fraction F was signiﬁcantly decreased at both the low and high doses of ACY-738
(n ≥ 3; *p b 0.05, **p b 0.005, ***p b 0.0005).
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−80 °C.2.13. Real-time RT-PCR
IL-6, IL-10 and TGF-β mRNA expressions were measured using
TaqMan Gene Expression assays (Applied Biosystems, Carlsbad, CA,
USA). The ΔΔCT was calculated using the endogenous control GAPDH,
and then the ΔCT was determined by calculating the fold change in ex-
pression between the NZB/W mice treated with ACY-738 and the
DMSO-treated controls. All samples were run in triplicate.2.14. ELISA
IL-1β and TGF-β levels were measured from the sera by ELISA ac-
cording to the manufacturer's protocol (eBioscience, San Diego, CA,
USA). The platewas read at 450 nmon amicroplate spectrophotometer.2.15. Statistics
Statistical analysis was performed using Student's unpaired t-test
(two-tailed). A linear regression analysis was used to determine the re-
lationship between age and cytokine production following treatment
64 N.L. Regna et al. / Clinical Immunology 162 (2016) 58–73with ACY-738. P values less than 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. BM differentiation of B cells is altered in diseased NZB/W mice
During B cell development in the BM, autoreactive B lymphocytes
can be removed by a number of mechanisms. In SLE, one or more of
these mechanisms may be defective at each of the B cell development
stages. To determine if B cell development was altered in the BM of
lupus mice, pro- and pre-B cell differentiation was evaluated in pre-
diseased and diseased NZB/W mice. BM cells were harvested from
NZB/W mice at 8 (pre-diseased) or 38 weeks-of-age (diseased) and
sorted into pro-B cell (CD43+B220+) and pre-B cell (CD43−B220+)
populations (Fig. 1A–B). There were no signiﬁcant differences in theFig. 4. ACY-738 had no effect on splenic or peripheral B cells. (A) Single cell suspension of splen
hiCD23+AA4.1+CD21+), T3 (IgMloCD23+AA4.1−CD21+), F0 (IgM+CD23+AA4.1−CD21−),MZ
icant differences followingHDAC6 inhibition in any of the splenic B cell developmental (B) Repr
effect on the percentage of peripheral B cells at either the low or high dose HDAC6i (n ≥ 3).percentages of pro- or pre-B cells between diseased and pre-diseased
mice (Fig. 1B).
To characterize B cell development further, pro-B cells were divided
into developmental fractionsA (B220+CD43+CD24−BP1−), B (B220+-
CD43+CD24+BP1−), C (B220+CD43+CD24loBP1+), and C’ (B220+-
CD43+CD24hiBP1+) (Fig. 1C–D). Diseased NZB/W mice had
signiﬁcantly fewer cells in fractions C and C′ when compared to pre-
diseased mice (Fig. 1D). Pre-B cells were further divided into fractions
D (B220+CD43− IgM− IgD−), E (B220+CD43− IgM+IgD−) and F
(B220+CD43− IgM+IgD+) (Fig. 1E–F). Diseased NZB/W mice had
markedly fewer cells in fractions D and E, but a signiﬁcant increase in
the percentage of cells in fraction F (Fig. 1F). Diseased NZB/W mice
have increased survival of cells during BM B cell differentiation leading
to an accumulation of cells in the late pre-B cell fraction F. These results
suggest that BM B cell development progresses more rapidly through
developmental stages during SLE disease, without the proper removalocytes were divided into developmental stages T1 (IgM+CD23−AA4.1+CD21−), T2 (IgM-
(IgM+CD23−AA4.1−CD21+), andB1 (IgM+CD23−AA4.1−CD21−). Therewere no signif-
esentativeﬂow cytometry diagramof peripheral B cells (IgM+B220+). (C) ACY-738had no
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Fig. 5. The percentage of DN thymic T cells is reduced following HDAC6 inhibition.
(A) Representative ﬂow cytometry images of thymocytes gated on CD3 and labeled with
CD4 and CD8. (B) ACY-738 treatment decreased the percentage of DN T cells in a dose-de-
pendent manner. (C) There was a reduction in the percentage of CD3+CD4+CD8− and
(D) CD3+CD4−CD8+ T cells following HDAC6 inhibition. (E) Double positive (CD3+-
CD4+CD8+) thymic T cell numbers were increased in a dose-dependent manner follow-
ing 16 weeks of treatment with ACY-738 (n ≥ 3; *p b 0.05, **p b 0.005).
66 N.L. Regna et al. / Clinical Immunology 162 (2016) 58–73of defective B cells leading to an increased number of autoreactive B
cells leaving the BM.
3.2. Selectivity and bioavailability of ACY-738 were determined
ACY-738 is a HDAC6 selective inhibitor [49]. To determine the dose
that would achieve a plasma concentration of approximately 2 nM for
up to 4, we performed a pharmacokinetic study using a single dose of
ACY-738 (5 mg/kg) by i.p. injection. We found that the plasma levels
4 h after the dose average 5.6 nM (Fig. 2). A dose four fold higher than
this was also well tolerated in mice and would be expected to extendFig. 6. Speciﬁc HDAC6 inhibition increased the Treg phenotype in NZB/W mice. (A) Repres
(B) Treatment with ACY-738 signiﬁcantly increased the percentage of Treg cells (CD4+Foxp3+the biologically active concentration for several hours longer. These
doses would be expected to induce the acetylation of histones through
class I HDAC inhibition, although for a shorter time period [50].
3.3. Treatment with ACY-738 alters BM B cell differentiation in vivo
We tested whether pharmacologic inhibition HDAC6 would be able
to alter B cell BM differentiation in NZB/W mice. Following treatment
with ACY-738, the percentage of pro- and pre-B cells was determined
using ﬂow cytometric analysis. The percentage of pro-B cells was not
signiﬁcantly altered following HDAC6 inhibition (Fig. 3A–B). However,
the treatment did alter the percentage of cells in developmental frac-
tions A, B, C, and C′ by increasing the percentage of cells in fractions A
and C (Fig. 3C–D). The pre-B cell populationwas signiﬁcantly decreased
in a dose-dependent manner following HDAC6 inhibition in NZB/W
mice (Fig. 3A, E). The developmental pre-B cell stages were also signiﬁ-
cantly altered. At both the 20 mg/kg BW dose and 5 mg/kg BW dose of
ACY-738, there was a signiﬁcant increase in the percentage of cells in
fractions D and E that corresponded with a decrease in cells in fraction
F (Fig. 3F–G).
3.4. Splenic and peripheral B cell populations were not signiﬁcantly altered
by HDAC6 inhibition
Previous studies have shown abnormal numbers of splenic B cells
from SLE patients in the transitional and MZ developmental stages
[51]. We tested whether treatment with ACY-738 was able to correct
the abnormal populations of splenic B cells in lupus-pronemice. Splenic
B cellswere sorted into their developmental stages T1, T2, T3, F0, B1, and
MZ. However, treatmentwith ACY-738 did not signiﬁcantly affect these
populations of B cells at either the 20 mg/kg BW dose or 5 mg/kg BW
dose (Fig. 4A).
We investigatedwhether HDAC6 inhibitionwas able to alter periph-
eral B cell populations since previous reports have shown that there areentative ﬂow diagram of splenocytes gated on CD4 and labeled with Foxp3 and CD25.
CD25+) (n ≥ 5; *p b 0.05).
67N.L. Regna et al. / Clinical Immunology 162 (2016) 58–73major differences in peripheral B cells between SLE patients and healthy
controls [19,52]. A single-cell suspension was obtained from the blood
of 38-week-old NZB/Wmice and strained for IgM and B220. Treatment
had no effect on the percentage of peripheral B cells (IgM+B220+) in
38-week-old NZB/Wmice (Fig. 4B–C).
3.5. Inhibition of HDAC6 alters thymic T cell development
SLE patients and lupus-prone murine models have been reported to
have abnormal expression of T cells [7,53,54]. Of particular interest is an
increase in the DN (CD3+CD4−CD8−) T cell population. It is believed
that theDN T cell population can lead to the induction of pathogenic au-
toantibodies. We tested whether treatment with ACY-738 was able to
alter the percentage of DN T cells. HDAC6 inhibition resulted in a sub-
stantial decrease in CD4−CD8− T cells coupled with a signiﬁcant in-
crease in DP (CD3+CD4+CD8+) T cells (Fig. 4B, D). There were alsoFig. 7.Assessment of survival rate and disease progression in NZB/Wmice. (A) By 38weeks-of-a
theHDAC6i diedbefore termination of the study. (B) Bodyweight increased asNZB/Wmice aged
Wmice treated with the vehicle control alone. There was no signiﬁcant weight loss in mice th
mice being treatedwith ACY-738 (5mg/kg inDMSO), ACY-738 (20mg/kg inDMSO) or vehicle
mice treated with the vehicle control or the low-dose of ACY-738 aged. However, treatment
(D) Average spleen weight by group was determined following euthanization of mice at 38
(E) Spleen:body weight ratio was calculated and multiplied by 100. Treatment with ACY-738
**p b 0.005).signiﬁcant decreases in the number of CD3+CD4+CD8− and CD3+-
CD4−CD8+ single positive (SP) T cells, but an increase in the percentage
of double positive (CD3+CD4+CD8+) T cells (Fig. 5B, C).3.6. Inhibition of HDAC6 increased the number of regulatory T cells in the
spleen
The Treg phenotype was assessed due to its role in the maintenance
of self-tolerance and the prevention of autoimmune disease [55]. During
active SLE the overall number and function of Treg cells is reduced [56].
Splenocytes were obtained from 38-week-old NZB/Wmice and stained
with CD4, CD25, and Foxp3. Treatment with ACY-738 resulted in a sig-
niﬁcant increase in the percentage of Treg cells at the 20 mg/kg BW
dose and 5mg/kg BWdose compared tomice treated with vehicle con-
trol alone (Fig. 6A–B).ge, half of the NZB/Wmice receiving the vehicle control alone had died. Nomice receiving
, untilmice reached the terminal stage of disease. Therewas signiﬁcantweight loss inNZB/
at received ACY-738 treatment. (C) Measurement of proteinuria every 2 weeks in NZB/W
control (DMSO) from22 to 38weeks-of-age. Proteinuria gradually increased as theNZB/W
with the high-dose of ACY-738 prevented proteinuria from increasing in NZB/W mice.
weeks-of-age. HDAC6 inhibition signiﬁcantly decreased spleen weight in NZB/W mice.
decreased the spleen:body weight ratio in a dose-dependent manner (n ≥ 5; *p b 0.05,
Fig. 7 (continued).
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nary markers of SLE and splenomegaly
HDAC6 inhibition was evaluated for its efﬁcacy in decreasing SLE
markers of disease and prolonging the survival of NZB/W mice. All
mice receiving either the 20 mg/kg BW dose and 5 mg/kg BW dose of
ACY-738 survived to the completion of the study. However, half of the
NZB/Wmice receiving the vehicle control alone died before termination
of the study at 38weeks-of-age (Fig. 7A). Bodyweight increased as NZB/
W mice aged following treatment with ACY-738. Vehicle control-
treated NZB/W mice experienced weight loss concomitantly with in-
creased proteinuria (Fig. 7B). Throughout the treatment period, NZB/
W mice were monitored for changes in proteinuria and body weight.
Treatmentwith 20mg/kg ACY-738 signiﬁcantly attenuated the severity
of proteinuria in NZB/W F1 mice (Fig. 7C). Because SLE is characterized
by enlargement of the spleen, splenomegaly was assessed in mice fol-
lowing euthanasia by determining the total spleen weight along with
the spleen:body weight ratio. Both spleen weight and spleen:body
weight ratio were decreased following HDAC6 inhibition in a dose de-
pendent manner (Fig. 7D–E).3.8. Treatment with ACY-738 reduced serum anti-dsDNA and altered Ig
isotype levels
Ig isotype levels were assessed due to previous studies linking ele-
vated IgG levels to glomerulonephritis in both NZB/W mice and
human SLE [57]. Diseased NZB/W mice have elevated production of
anti-dsDNA as well as increased production of IgM and IgG isotypes
(speciﬁcally IgG2a) [58]. To determine the effect of speciﬁc HDAC6 inhi-
bition on disease in NZB/W mice, serum anti-dsDNA and Ig isotype
levels were measured every 4 weeks beginning at 22 weeks-of-age.
Anti-dsDNA, IgG2a, and total IgG levels gradually increased as the
mice aged (Fig. 8A–C). There were no signiﬁcant differences between
the groups in anti-dsDNA at 22 weeks-of-age. Treatment with thehigh dose of ACY-738 was able to prevent an increase of anti-dsDNA
as the mice aged. NZB/Wmice that received 5 mg/kg ACY-738 showed
a signiﬁcant decrease in anti-dsDNA production as they aged when
compared to vehicle control-treated mice (p b 0.05). Following treat-
ment with the 20mg/kg dose, the decrease in autoantibody production
was more pronounced compared to NZB/W mice that received the
lower dose or vehicle control alone (Fig. 8A). TheHDAC6i treatment sig-
niﬁcantly decreased levels of IgG2a and total IgG (Fig. 8B–C).
3.9. HDAC6 inhibition prevented TGF-β and IL-1β production frombeing al-
tered as NZB/W mice aged
Elevated IL-1β levels have been reported to play a role in the patho-
genicity of a number of autoimmune diseases including SLE [59,60].
Conversely, lymphocyte production of TGF-β has been shown to be de-
creased during active SLE [61]. Beginning at 22 weeks-of-age, cytokine
levels were measured in the sera every 4 weeks until euthanasia at 38
weeks-of-age (Fig. 9A–B). As the NZB/W mice aged, sera levels of TGF-
β decreased whereas levels of IL-1β increased (Fig. 9A–B). HDAC6 inhi-
bition attenuated the reduction of TGF-β production as themice aged in
a dose-dependent manner (Fig. 9A). Treatment with both the low and
high dose of ACY-738 attenuated sera IL-1β production as the NZB/W
mice aged (Fig. 9B).
3.10. Glomerular IL-10, TGF-β, and IL-6 mRNA expression is decreased fol-
lowing HDAC inhibition in vivo
Wenext sought to determinewhether ACY-738would alter glomer-
ular mRNA expression in NZB/W mice. NZB/W mice develop renal dis-
ease around 20 weeks-of-age, progressing to severe
glomerulonephritis by 36 weeks-of-age [62]. Altered mRNA glomerular
expression can lead to ﬁbrosis and irreversible glomerular damage [63].
The balance between Th1 and Th2 cytokines plays a critical role in the
immune response and the pathogenesis of autoimmune disease. IL-10
has been reported to be elevated in SLE and plays a critical role in B
cell survival, differentiation, and Ig secretion. Inhibiting IL-10 has been
demonstrated to decrease disease; while administration of IL-10 has
been shown to accelerate disease in lupus-prone mice [64]. TGF-β has
been shown to play a dual role in SLE pathogenesis. In NZB/W mice,
TGF-β is produced in the kidneys to counter inﬂammation resulting
from autoantibody production [65]. IL-6 induces polyclonal B-cell acti-
vation and autoantibody production during SLE. Studies have demon-
strated increased expression of the proinﬂammatory cytokine, IL-6, in
lupus kidneys [66].
Following euthanasia, glomeruli were isolated from the kidneys and
RNAwas extracted. Relative glomerularmRNA expression of IL-10, TGF-
β, and IL-6were determined using real-time RT-PCR. Administration of
ACY-738 (5mg/kg) was able to signiﬁcantly reduce glomerular IL-6 and
IL-10 mRNA levels by more than 50% while treatment with 20 mg/kg
ACY-738 reduced IL-6 and IL-10 mRNA to non-detectable levels
(Fig. 10). Furthermore, glomerular TGF-βmRNA was decreased follow-
ing inhibition of ACY-738 in a dose-dependent manner (Fig. 10). Taken
together these results suggest that HDAC6 inhibition by ACY-738 re-
duces production of SLE-associated cytokine mRNA.
3.11. Glomerular immune complex deposition is reduced following HDAC6
inhibition
We sought to determinewhether ACY-738 decreased immune com-
plex deposition and complement activation in renal tissue. Treatment
with the high-dose of ACY-738 was able to decrease both the number
of glomeruli with C3 and IgG deposition as well as the overall level of
deposition within each glomerulus (Fig. 11A). Mice that received
5 mg/kg ACY-738 had a slight decrease in C3 and IgG deposition (data
not shown). Treatmentwith 20mg/kg of ACY-738 resulted in decreased
IgG andC3 staining compared to vehicle control-treatedmice (Fig. 11B).
Fig. 9. Cytokine production in lupus-prone mice was assessed. (A–B) TGF-β and IL-1β
were measured in sera collected from mice prior to treatment (22 week-of-age) and fol-
lowing HDAC6i treatment for 16 weeks. At 22 weeks-of-age there were no signiﬁcant dif-
ferences in cytokine levels amongst the three groups. (A) Following treatment, TGF-β
levels had signiﬁcantly decreased in vehicle control-treated mice, however, treatment
with ACY-738 was able to reverse this trend in a dose-dependent manner. (B) Levels of
IL-1β were elevated in 38-week-old NZB/W mice. HDAC6 inhibition signiﬁcantly de-
creased sera IL-1β (n ≥ 3; *p b 0.05, ***p b 0.0005).
Fig. 8. Evaluation of SLE sera biomarkers of disease inNZBWmice following ACY-738 ther-
apy. (A) Measurement of sera anti-dsDNA in NZB/W mice at 22 weeks-of-age (prior to
treatment) and 38weeks-of-age (following 16weeks of treatment). Therewere no signif-
icant differences in anti-dsDNA levels prior to the initiation of treatment. Anti-dsDNA in-
creased in the NZB/Wmice as they aged; however, HDAC6 inhibitionwas able to decrease
production in 38-week-oldmice. (B) At 38 weeks-of-age, total IgG was slightly decreased
in mice that received the HDAC6i. (C) IgG2a levels were measured prior to initiation of
treatment and prior to euthanization at 38 weeks-of-age. Anti-dsDNA levels increased
over time, but ACY-738 treatment signiﬁcantly decreased IgG2a in a dose-dependent
manner. (n ≥ 5; *p b 0.05, **p b 0.005).
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Treatment with the 20 mg/kg dose signiﬁcantly decreased IgG and C3
deposition, however, 5 mg/kg ACY-738 showed no signiﬁcant effect
on IgG and C3 deposition compared to mice that received vehicle con-
trol alone (Fig. 11C–D).
3.12. HDAC6 inhibition decreased SLE renal pathology
In order to assess renal disease, kidney sections were embedded in
parafﬁn and stained by PAS. NZB/W mice have been shown to develop
severe renal disease by 32 weeks-of-age. NZB/W mice treated with
DMSO alonehad thickened, irregular glomerular basementmembranes,
increased cellularity, ﬁbrosis and crescent formation (Fig. 12A).Treatment with 5 mg/kg ACY-738 did not signiﬁcantly alter kidney pa-
thology. However, kidneys frommice treatedwith 20mg/kg of ACY-738
had signiﬁcantly reduced SLE renal pathology characterized by the lack
of ﬁbrosis and crescent bodies (Fig. 12B). All kidneys were scored (0–4)
by a pathologist, in a blinded manner. NZB/W mice that were treated
with the vehicle control alone received an average score of 4 compared
to an average score of 2 from mice that received the high-dose of ACY-
738 (Fig. 12C).
4. Discussion
In our studies, we found altered differentiation of B cells in the BMof
diseased NZB/W mice characterized by increased survival of differenti-
ating B cells resulting in the accumulation of cells in the late pre-B cell
fraction, F. Furthermore, diseased NZB/W mice had decreased percent-
ages of cells in the late pro-B cell/early pre-B cell phases when com-
pared to pre-diseased mice. Treatment with ACY-738 was able to
reverse these abnormalities by altering percentages of cells in late
pro- and early pre-B cells fractions, and more speciﬁcally decreasing
the accumulation of B cells in fraction F. HDAC6 inhibition was also
able to alter T cell differentiation evidenced by increased Treg cells
and decreased thymic DN T cells after 16 weeks of HDAC6i therapy.
These results suggest that B and T cell differentiation play an important
role in SLE pathogenesis and that inhibition of HDAC6 may be effective
in correcting aberrant lymphocyte development. Indeed, a B cell
Fig. 10. Glomerular mRNA levels were assessed in 38-week-oldmice. Relative glomerular
levels of IL-6, IL-10, and TGF-βmRNAwere determined using real time RT-PCR. Treatment
with ACY-738 decreased IL-6, IL-10, and TGF-β in a dose-dependent manner. Following
treatment with 20 mg/kg ACY-738, IL-6 and IL-10 were undetectable (n ≥ 5; *p b 0.05,
**p b 0.005, ***p b 0.0005).
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tration (FDA) approval for its use in SLE [67]. Furthermore, other new
drugs inhibit the proteasome and immune cell signaling molecules
such as Btk, ROCK and CaMK4 are actively being investigated as lupus
therapies [68].
Normally, B cells that develop autoreactive B cell receptors (BCRs)
are removed by both positive and negative selection from the BM in
three ways: receptor editing, deletion, and anergy [10]. In healthy indi-
viduals, approximately 55–75% of the repertoire produced by Ig geneFig. 11. HDAC6 inhibition decreased glomerular immune complex deposition. 5 μM kidney sec
(A–B) Representative images of glomerular deposition of both C3 and IgG in NZB/Wmice treate
evaluated by a pathologist in a blinded manner and scored (0–4) for the level and frequency
16 weeks of ACY-738 treatment (n ≥ 5; *p b 0.05, **p b 0.005).rearrangement in the BM is autoreactive [69]. These autoreactive B
cells are removed at two checkpoints [17]. The majority of autoreactive
B cells are removed in the BM while the cells are still immature [70].
Previous studies have shown that early checkpoints during B cell devel-
opment in theBMare abnormal in SLE resulting in increased numbers of
self-reactive B cells in circulation [69]. The current studies support the
notion that there exists a defect in one or more of the developmental
checkpoints during BM B cell development. While our study showed
no difference in the overall number of pro- or pre-B cells between
pre-diseased and diseased NZB/Wmice, there were altered proportions
of cells in the pro- and pre-B cell developmental fractions. When com-
pared to pre-diseased mice, diseased NZB/Wmice had decreased num-
bers of B cells in late pro-B cell fractions (C and C′) and early pre-B cell
fractions (D and E). There was also a notable increase in the percentage
of B cells in the late pre-B stage, fraction F. These data suggest that dis-
eased NZB/Wmice are unable to support proper B cell differentiation in
the BM possibly due to altered regulation of developmental check-
points, resulting in failure to remove defective B cells. It was noted
that while Fr.'s C and C′ were decreased in diseased mice compared to
the control (Fig. 1D), treatment with ACY-738 led to increases of Fr. A
and Fr. C in the bone marrow of these mice (Fig. 3D). It is likely that in-
hibition of HDAC6 blocked two distinct checkpoints of B cell
development—i.e., the stages represented by Fr. B and Fr. D,
respectively—causing cells of Fr. A and Fr. C/C′ to accumulate. A common
feature of Fr. B and Fr. D are enhanced activities of Rag1 and Rag2 that
control V(D)J recombination of μH locus and κ locus, respectively [10].
Thus, we speculate that HDAC6i could potentially cause cytoplasmic se-
questration of Rag2, which is known to be translocated out of thetions were stained with FITC-conjugated C3 or IgG and assessed for ﬂuorescence intensity.
d with the vehicle control or the high dose of ACY-738. (C–D) IgG and C3 deposition were
of ﬂuorescence. Both IgG and C3 deposition levels were signiﬁcantly decreased following
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Fr.'s B and D [71]. Under normal conditions, the apoptotic index and the
apoptotic rate, for the removal of autoreactive B cells, are greatest
around the pro/pre-B cell transition [70,72]. Our results show that the
greatest difference in the alteration of B cell development in diseased
NZB/Wmice occurs at the pre-B/pro-B stages indicating a possible apo-
ptotic defect in the bone marrow.
ACY-738 is a selective HDAC6 inhibitor with minimal reactivity
against other class II HDACs and 100-fold less selectivity against class I
HDACs [49]. Jochems et al. showed a dose-dependent enzymatic selec-
tive inhibition of recombinant HDCA6 over HDACS 1, 2, and 3 following
treatment with ACY-738. Class I HDAC inhibition is known toFig. 12. SLE-associated renal pathology was decreased following ACY-738 therapy. Parafﬁn-em
severe glomerulonephritis (thickened GBM and crescent formations) from an NZB/W mouse t
W mice had improved renal pathology. (C) Sections were assessed for glomerular proliferatio
blinded pathologist, and a glomerular score (0–4) was assigned. The ACY-738 treatment signiﬁsigniﬁcantly reduce the total number of peripheral lymphocytes [49].
There was no signiﬁcant difference in the numbers of peripheral lym-
phocytes, WBCs, RBCs, or platelets between treatment groups, indicat-
ing further that Class I HDACs were not inhibited by ACY-738.
After immature B cells leave the BM, they continue to develop in sec-
ondary lymphoid organs including the spleen [10]. As immature B cells
develop into mature B cells they become antigen-speciﬁc [10]. B cells
that escape negative selection during BM differentiation may mature
in the spleen to becomemarginal zone or follicular cells [73]. IgM+IgD+
B cells leave the BM as transitional cells and enter the spleenwhere they
mature into follicular B cells or marginal-zone B cells [10,73]. ACY-738
did not alter the percentages of B cells in transitional, follicular orbedded kidneys were sectioned and then stained with PAS. (A) Representative image of
reated with the vehicle control alone. (B) When treated with ACY-738 (20 mg/kg), NZB/
n, inﬂammation, number of nuclei per glomerulus, crescent formation, and ﬁbrosis by a
cantly decreased SLE kidney pathology (n ≥ 5; *p b 0.05).
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ing early B cell development in the BM and not on peripheral or splenic
B cells.
Anti-dsDNA is produced by autoreactive B cells that escape negative
and positive selection during B cell development [3,17]. Our studies
showed that as NZB/Wmice aged, auto-antibody production increased,
which correspondedwith a concomitant increase in proteinuria. IgG au-
toantibodies are responsible for glomerulonephritis associated with
SLE.When IgG autoantibodies encounter antigen, they bind to form im-
mune complexes that become lodged in renal glomeruli, resulting in in-
creased activation of the immune system and inﬂammation [74]. The
damaged kidneys are then unable to properly ﬁlter proteins, which
pass into the urine and cause elevated levels of proteinuria [3]. Our
study showed that decreased IgG production in the sera following
HDAC6 inhibition, correlated with reduced glomerular immune com-
plex deposition, SLE-associated kidney pathology, and proteinuria.
This indicates that although ACY-738 does not affect numbers of periph-
eral B cells, it does alter mature plasma cell production of
autoantibodies.
Our results showed that inhibition of HDAC6 is able to increase the
Treg phenotype, which correlated with a decrease in SLE-associated
markers of disease. Treg cells have been shown to directly inﬂuence Ab
production as depletion of Treg cells in mice leads to overproduction of
Abs. Conversely, adoptive transfer of Treg cells to autoimmune prone
mice, signiﬁcantly decreases Ab production and disease pathology [75,
76]. At 38 weeks-of-age, NZB/Wmice that received 20 mg/kg ACY-738
had signiﬁcantly higher numbers of Treg cells and reduced levels of auto-
antibody production when compared to vehicle control-treated mice.
Previous research has shown that treatmentwith ACY-738 is able to in-
crease the suppressive function of Treg cells in vitro [42]. Research indi-
cates that a decrease in Treg numbers and functionmay contribute to SLE
pathogenesis due to their important role in the regulation of the im-
mune system and the suppression of autoantibody-producing B cells
[56,77]. Studies have reported that Treg cell numbers are reduced during
active SLE, but numbers are increased following treatment and clinical
improvement [56]. It has been demonstrated that pan-HDAC inhibitors,
but not class I speciﬁc HDAC inhibitors, are able to increase populations
of Treg cells [39]. It is possible that HDAC inhibition may stabilize Treg
cells and enhance their suppressive function [78].
Naïve CD4+ T cells differentiate into Treg cells following TGF-β stim-
ulation,whichpromotes Foxp3 expression [79]. Our results showed that
as NZB/W mice aged, sera TGF-β levels were reduced; however, treat-
ment with ACY-738 was able to ameliorate the reduction of TGF-β in a
dose-dependent manner. This correlated with an increase in the Treg
population in NZB/Wmice treated with ACY-738. Conversely, glomeru-
lar mRNA expression of TGF-β was decreased following HDAC6i treat-
ment indicating a dual role of TGF-β in SLE pathogenesis. Previous
studies have shown a correlation between decreased TGF-β levels in
lymphoid tissues and an increase in autoantibody production leading
to a proinﬂammatory environment [65]. Anti-inﬂammatory cytokines
including TGF-β are produced in order to combat inﬂammation within
target organs such as the kidneys. The increased production of anti-
inﬂammatory cytokines causes deposition of extracellularmatrix andﬁ-
brosis [80]. Elevated levels of TGF-β in immune cells can coincide with a
reduction in TGF-β in target organs leading to autoimmune disease in-
cluding lupus [65,80,81]. Our results showed the ability of HDAC6 inhi-
bition to reverse these trends by increasing the sera levels of TGF-β to
induce a Treg phenotype, while decreasing TGF-β in the glomeruli of
the kidneys that may lead to ﬁbrosis.
During SLE there is an imbalance between the production of Th1 and
Th2, and Th17 cytokines [82,83]. We investigated whether HDAC6i
therapy was able to reverse altered IL-6, IL-10, and IL-1β cytokine pro-
duction trends that are characteristic of SLE. Following treatment with
ACY-738 (20 mg/kg), IL-6 was undetectable in the kidneys of NZB/W
mice. The proinﬂammatory cytokine IL-6 is upregulated in SLE and con-
tributes to overproduction of IgG [84,85]. The reduction in IL-6correlated with a decrease in total IgG and the IgG2a isotype levels in
the sera. Similarly, elevated levels of the proinﬂammatory cytokine IL-
1β have been reported to play a role in the pathogenicity of a number
of autoimmune diseases including SLE [86,87]. In lupus-prone mice
that are deﬁcient in IL-1β, sera levels of autoantibodies are decreased
and the manifestation of disease is much milder [88]. Our results indi-
cate that ACY-738 is able to decrease IL-1β in a dose-dependentmanner
and correlates with the reduction in dsDNA autoantibody levels.
Our studies showed that ACY-738 decreased several characteristics
of SLE in NZB/Wmice by dictating B cell development in the bone mar-
row. We found that there was a decrease in the percentage of cells in
early B cell developmental stages and an increase in the number of
cells in late B cell BM developmental stages during disease in NZB/W
mice. ACY-738 treatment increased the percentage of B cells in early de-
velopmental stages, while decreasing the percentage of cells in late pre-
B cell fraction F. ACY-738 regulation of BM B cell development could be
due to regulation developmental checkpoints known to be dysfunction-
al during SLE. Studies are currently underway to deﬁne the mechanism
through which ACY-738 regulates abnormal B cell development ob-
served in SLE.Financial support
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